Navigation Links
Amicus Therapeutics to Present at Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011

CRANBURY, N.J., May 31, 2011 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Matthew R. Patterson, President and Acting Chief Executive Officer, will present a corporate overview at the Jefferies 2011 Global Healthcare Conference in New York, NY on Tuesday, June 7 at 12:15 p.m. ET.

A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at, and will be archived for 90 days. Participants are encouraged to visit the web site 10 minutes prior to the start of the presentation to register, download and install any necessary software.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. Amicus' lead program Amigal(tm) (migalastat HCl) is in Phase 3 for the treatment of Fabry disease.


SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Amicus Therapeutics Announces First Quarter 2011 Financial Results and Continued Progress of Development Programs
2. Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman
3. Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease
4. Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
5. Amicus Therapeutics to Present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011
6. Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinsons Disease
7. Amicus Therapeutics Announces Third Quarter 2010 Financial Results
8. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
9. Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
10. Amicus Therapeutics to Host Its Second Quarter 2010 Financial Results Conference Call and Webcast on August 5, 2010
11. Amicus CEO Represents BIO on Rare Diseases at U.S. Senate Committee on Health, Education, Labor and Pensions Bipartisan Hearing
Post Your Comments:
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
Breaking Medicine Technology:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):